WO1993019720A3 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO1993019720A3
WO1993019720A3 PCT/US1993/002230 US9302230W WO9319720A3 WO 1993019720 A3 WO1993019720 A3 WO 1993019720A3 US 9302230 W US9302230 W US 9302230W WO 9319720 A3 WO9319720 A3 WO 9319720A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
useful
production
phosphodiesterase
exacerbated
Prior art date
Application number
PCT/US1993/002230
Other languages
French (fr)
Other versions
WO1993019720A2 (en
Inventor
Siegfried Benjamin Christensen
Paul Elliot Bender
Cornelia Jutta Forster
John Gerald Gleason
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to EP93907430A priority Critical patent/EP0633771A4/en
Priority to JP51745993A priority patent/JP3199380B2/en
Priority to MA23151A priority patent/MA22860A1/en
Priority to SI9300166A priority patent/SI9300166A/en
Publication of WO1993019720A2 publication Critical patent/WO1993019720A2/en
Publication of WO1993019720A3 publication Critical patent/WO1993019720A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Novel compounds of Formulas (I) and (II) are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV.
PCT/US1993/002230 1992-04-02 1993-03-12 Compounds WO1993019720A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP93907430A EP0633771A4 (en) 1992-04-02 1993-03-12 Compounds.
JP51745993A JP3199380B2 (en) 1992-04-02 1993-03-12 Compound
MA23151A MA22860A1 (en) 1992-04-02 1993-04-01 PROCESS FOR THE PREPARATION OF NEW COMPOUNDS.
SI9300166A SI9300166A (en) 1992-04-02 1993-04-02 New compounds useful for treating or inhibiting phosphodiesterase iv (pde iv) enzyme activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86211492A 1992-04-02 1992-04-02
US07/862,114 1992-04-02
US96880692A 1992-10-30 1992-10-30
US07/968,806 1992-10-30
USPCT/US93/02046 1993-03-05
US9302046 1993-03-05

Publications (2)

Publication Number Publication Date
WO1993019720A2 WO1993019720A2 (en) 1993-10-14
WO1993019720A3 true WO1993019720A3 (en) 1993-11-25

Family

ID=27377344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002230 WO1993019720A2 (en) 1992-04-02 1993-03-12 Compounds

Country Status (3)

Country Link
EP (1) EP0633771A4 (en)
JP (1) JP3199380B2 (en)
WO (1) WO1993019720A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115872B1 (en) * 1992-04-02 2000-07-28 Smithkline Beecham Corp Substituted phenylcarboxylic acid derivatives and pharmaceutical composition comprising the same
SK279958B6 (en) * 1992-04-02 1999-06-11 Smithkline Beecham Corporation Compounds exhibiting anti-allergic and anti-inflammatory properties, pharmaceutical composition them containing and their use
WO1996020175A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 1,4,4-(trisubstituted)cyclohex-1-ene derivatives as pde iv- and tnf-inhibitors
WO1996019978A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 1,3,3-(trisubstituted)cyclohex-1-ene dimers and related compounds
JPH10511390A (en) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション 1,4,4- (Trisubstituted) cyclohex-1-endimer and related compounds
US5900417A (en) * 1995-12-21 1999-05-04 Smithkline Beecham Corporation 1,3,3-(Trisubstituted)cyclohexanemonomers and related compounds
UY25338A1 (en) * 1998-01-07 2001-08-27 Smithkline Beecham Corp METHOD FOR TREATING COPD
DE60043318D1 (en) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistic combination of pumafentrine and salmeterol
ATE450498T1 (en) * 2002-12-23 2009-12-15 4Sc Ag CYCLOALKENEDICARBONIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATOR AND ANTIPROLIFERATIVE AGENTS
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (en) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Inhibitors of phosphodiesterases in infertility
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
JP6694385B2 (en) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS 2, July 1990, (MUKHERJEE, A. et al.), Vol. 113, No. 1, Abstract 5823S, see Formula II. *

Also Published As

Publication number Publication date
EP0633771A1 (en) 1995-01-18
EP0633771A4 (en) 1995-02-22
JPH08500815A (en) 1996-01-30
WO1993019720A2 (en) 1993-10-14
JP3199380B2 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
WO1993019720A3 (en) Compounds
CA2133337A1 (en) Compounds useful for treating allergic or inflammatory diseases
CA2133439A1 (en) Compounds useful for treating allergic and inflammatory diseases
AU6626696A (en) Quinolones and their therapeutic use
MX9301903A (en) COMPOUNDS.
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
CA2315647A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
BG101130A (en) Inhibitors of interleukin-1-converting enzyme
CA2181175A1 (en) Dihydro Pyrazolopyrroles
TW225532B (en)
NZ305940A (en) N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma
IL135921A0 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AP9100310A0 (en) Tnf inhibitors
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
CA2238376A1 (en) Benzofuran carboxamides and sulphonamides
PL326236A1 (en) Novel compounds - derivatives of sulphonylpyrimidine exhibiting anticarcinogenous effect and method of obtaining them
WO1994000555A3 (en) Compositions for the inhibition of protein hormone formation and uses thereof
WO1988008842A3 (en) SUBSTITUTED 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES AND MEDICAMENTS CONTAINING SAME
KR100344711B1 (en)
CA2066234A1 (en) Activation compounds and methods for nucleic acid sterilization
GR920100521A (en) Compounds.
GR920100519A (en) Compounds.
GR920100520A (en) Compounds.
GR920100518A (en) Compounds.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: BY

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: BY

WWE Wipo information: entry into national phase

Ref document number: 08313097

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1993907430

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993907430

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993907430

Country of ref document: EP